ArticleInvestigational new drugs2026

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

Khobe Chandran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.